FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.
What happened
FDA inspected DeVere Manufacturing's drug manufacturing facility at 1923 Beloit Ave., Janesville, WI, from June 2 to 4, 2025. Investigators found the company makes OTC hand sanitizer on the same equipment used for industrial cleaning products, including a strongly acidic toilet bowl cleaner, and that it skipped required release testing, component identity testing, and quality unit oversight. FDA also noted similar quality unit violations at a January 26 to February 2, 2018 inspection.
What FDA found
The company had no adequate written procedures for cleaning and maintaining equipment, and made drug products on the same equipment used for industrial detergents and disinfectants, risking cross-contamination.
21 CFR 211.67(b)It did not test each batch of hand sanitizer for identity and strength of the active ingredient, for impurities, or for objectionable microorganisms before release, including more than (b)(4) batches made with water unsuitable for drug use.
21 CFR 211.165(a) and 211.165(b)It did not test each incoming shipment of components such as benzalkonium chloride, ethanol, and glycerin for identity, and relied on suppliers' certificates of analysis without checking the suppliers' test results.
21 CFR 211.84(d)(1) and 211.84(d)(2)It did not test ethanol for methanol or glycerin for diethylene glycol and ethylene glycol, impurities that have caused lethal poisonings worldwide.
21 CFR 211.84(d)(1) and 211.84(d)(2)The quality unit did not review production records properly (out-of-specification results, reprocessing, label reconciliation went uninvestigated) and had no adequate written procedures for annual product reviews, complaints, recalls, training, and validation.
21 CFR 211.22The quality unit did not ensure the water used as the main ingredient was suitable, while labels list purified water as the first inactive ingredient.
21 CFR 211.22
What FDA wants
FDA tells the company to correct the violations promptly and reply in writing within 15 working days with what it has done and how it will prevent recurrence, or with a reason for delay and a schedule. The letter also asks for diethylene glycol and ethylene glycol test results within 30 calendar days and recommends hiring a qualified CGMP consultant.
Who should pay attention
- retailers and distributors selling store-brand or private-label hand sanitizers
- brands that buy OTC drug products from contract manufacturers
- companies that run drug and industrial chemical production on shared equipment
This is a summary. Read the original letter on fda.gov.